Velásquez Honored for Research on Optimization of Tuberculosis Treatment Regimens

Gustavo E. Velásquez, MD, MPH

Gustavo E. Velásquez, MD, MPH, of the Division of Infectious Diseases, received the Mentored Clinical Scientist Research Career Development Award (K08 AI141740) from the National Institute of Allergy and Infectious Diseases (NIAID), the Union Young Investigator Prize from the International Union Against Tuberculosis and Lung Disease (IUATLD) and the Maxwell Finland Award for Excellence in Research from the Massachusetts Infectious Diseases Society (MIDS) for his research on the optimization of tuberculosis treatment regimens.

Velásquez received the NIAID K08 Mentored Clinical Scientist Research Career Development Award for his role as principal investigator on the project, “Safety and Tolerability of New and Repurposed Drugs for MDR-TB Treatment.” This project examines the safety and tolerability of two medications, bedaquiline and delamanid, within conventional multidrug-resistant tuberculosis (MDR-TB) regimens; estimates how two dose-reduction strategies of another antibiotic, linezolid, affect the safety and tolerability of MDR-TB treatment and the pharmacokinetics of linezolid; and estimates the effect of plasma drug exposure on the safety and tolerability of combinations of new and repurposed drugs.

Velásquez was one of two recipients of the IUATLD’s 2019 Union Young Investigator Prize and was recognized at the 50th Union World Conference on Lung Health. The award acknowledges researchers for work in lung health published in the past five years, when aged 35 years or younger.

The Maxwell Finland Award for Excellence in Research is conferred annually by the MIDS for excellence in research. Velásquez was honored with this award in November for his contributions to research on the treatment of tuberculosis.

Velásquez’s main research interest is to develop safe, tolerable and effective treatment regimens for drug-susceptible and drug-resistant tuberculosis.

/Public Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.